New beginnings in cancer therapy

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® (VNP40101M) is underway in small cell lung cancer. Our second clinical-stage product, Triapine®, is being evaluated in several trials sponsored by the National Cancer Institute. Additional small molecule anticancer compounds are under development in preclinical studies.